From: The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study
 | Total (n = 218) | Death (N = 52, 24%) | Hazard ratio (95% CI) | Adjusted HR$(95% CI) | Adjusted HR#(95% CI) |
---|---|---|---|---|---|
Age at TB diagnosis (per 5-year increase) | Â | Â | 1.14 (1.03-1.27) | 1.12 (1.01-1.25) | 1.13 (0.97-1.32) |
CD4 count at TB diagnosis (per 50-cell increase) | Â | Â | 0.94 (0.83-1.06) | 0.81 (0.71-0.92) | 0.79 (0.60-1.05) |
IRIS | 57 | 5 (8.8%) | 0.26 (0.10-0.65) | 0.36 (0.14-0.97) | 0.36 (0.13-0.95) |
HAART initiation timing during anti-TB therapy | |||||
  No HAART | 36 | 23 (63.9%) | 1 | 1 |  |
  0–15 days | 110 | 19 (17.3%) | 0.17 (0.09-0.31) | 0.14 (0.07-0.27) | 0.97 (0.34-2.70) |
  16–30 days | 34 | 5 (14.7%) | 0.14 (0.05-0.36) | 0.10 (0.04-0.28) | 0.69 (0.19-2.49) |
  31–60 days | 19 | 0 (0%) | – | – | – |
  >60 days | 19 | 5 (26.3%) | 0.25 (0.10-0.67) | 0.14 (0.05-0.39) | 1 |